Orbis Medicines
Healthcare & Life Sciences
Recent Finacing
Series A
Recent Raise
$92.7M
Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.
Focus Areas
Oral macrocycle drugs
nCycles
Biologic alternatives
nGen platform
Automated chemistry
Machine learning
Investors
